Nyrada Inc. FULL YEAR RESULTS FY2023

Highlights:
• Research and development costs of $6.4M (FY2022: $1.8M), approximately 68% of expenditure.
• Accrued (estimated) R&D rebate of $1.3M (FY2022: $1.0M) expected to be received in 1HCY2023.
• Cash at bank $3.7M (FY2022: $10.8M).
• Good Laboratory Practice (GLP) safety and toxicity studies for cholesterol lowering program candidate NYX-1942 completed. Alternative PCSK9 inhibitor candidates under evaluation.
• GLP studies for brain injury candidate NYR-BI02 undertaken. Analog drug NYR-BI03 determined as superior candidate and advanced for studies which commenced in FY2024.
• Research paper published in the journal Translational Stroke Research validated Nyrada’s TRPC channel drug target for secondary brain injury neuroprotection.